Status of work in April
AOTMiT begins work on the Ministry of Health’s orders in April:
- Balversa (erdafitinib) in the treatment of urothelial cancer patients
- Repatha (evolocumab) in the treatment of patients with lipid disorders
- Keytruda (pembrolizumab) in the treatment of cervical cancer
- EpiPen Jr., EpiPen Senior (epinephrine), auto-injector for the emergency treatment of severe allergic reactions (anaphylaxis) to stings or bites of insects, food, medicines or other allergens, as well as idiopathic or exercise-induced anaphylaxis.
The listed orders are available on the AOTMiT Public Information Bulletin.